CHAIN Conference Attendance – Update September 2018
Ben Bradley, our Head of Partnerships and Licensing, is attending Gut-Brain Axis 2018, part of the Biotech Pharma Summit conference series in Paris September 6 & 7. This year’s event brings together leading scientists, physicians, and senior leaders to explore the brain and its engagement with the GI-nervous system axis in health and disease. Chief Executive Dr […]
CHAIN to Explore Manufacturing of Novel Medicines
UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome. The novel and highly innovative approach […]
CHAIN Awarded Two Grants to Develop High-Value Products
CHAIN has been awarded £0.5M grant funding from Innovate UK, the UK’s Innovation agency, to expand its range of biotechnology products. Building on a successful synthetic biology program, the grants support further development of CHAIN’s proprietary Clostridium platform for therapeutic and specialty chemical applications. A two-year project will focus on the development of novel therapeutics […]
Superior and effective microbiome therapeutics
About us
CHAIN Biotechnology Ltd develops Clostridium-based microbial technology for high-value healthcare products. We produce novel 2nd generation live biotherapeutic products for chronic gut-related diseases.
Platform
Our Clostridium Assisted Drug Delivery (CADDâ„¢) platform is a targeted, robust and versatile method of delivering therapeutic bioactives to the gut in a safe, proven and affordable way.
Pipeline
CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADDâ„¢ technology. Our lead product targets Inflammatory Bowel Disease.